AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Exelixis Inc

Healthcare US EXEL


Last update at 2024-02-22T20:52:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 234.35M 294.15M 130.84M 398.11M 452.09M
Minority interest - - - - -
Net income 182.28M 231.06M 111.78M 321.01M 690.07M
Selling general administrative 459.86M 401.71M 293.36M 228.24M 206.37M
Selling and marketing expenses - - - - -
Gross profit 1553.15M 1382.10M 951.27M 934.68M 827.48M
Reconciled depreciation 20.88M 13.63M 9.14M 8.35M 7.77M
Ebit 180.61M 273.04M 100.92M 361.12M 444.32M
Ebitda 201.48M 286.67M 110.06M 369.47M 452.09M
Depreciation and amortization 20.88M 13.63M 9.14M 8.35M 7.77M
Non operating income net other -0.19700M -0.18400M 0.91M 0.68M 0.40M
Operating income 201.48M 286.67M 110.06M 369.47M 438.86M
Other operating expenses 1409.58M 1148.30M 877.48M 598.30M 414.97M
Interest expense 53.74M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision 52.07M 63.09M 19.06M 77.10M -237.97800M
Interest income 33.06M 7.67M 19.86M 27.96M 12.84M
Net interest income 33.06M 7.67M 19.86M 27.96M 12.84M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 52.07M 63.09M 19.06M 77.10M -237.97800M
Total revenue 1611.06M 1434.97M 987.54M 967.77M 853.83M
Total operating expenses 1351.67M 1095.43M 841.21M 565.21M 388.62M
Cost of revenue 57.91M 52.87M 36.27M 33.10M 26.35M
Total other income expense net 32.87M 7.49M 20.78M 28.64M 13.24M
Discontinued operations - - - - -
Net income from continuing ops 182.28M 231.06M 111.78M 321.01M 690.07M
Net income applicable to common shares 182.28M 231.06M 111.78M 321.01M 690.07M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 3071.49M 2616.24M 2137.33M 1885.67M 1422.29M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 62.21M 57.53M 57.01M 26.99M 15.02M
Total liab 583.06M 405.62M 258.22M 199.70M 134.83M
Total stockholder equity 2488.43M 2210.61M 1879.11M 1685.97M 1287.45M
Deferred long term liab - - - - -
Other current liab 285.11M 313.33M 181.03M 21.72M 21.82M
Common stock 0.32M 0.32M 0.31M 0.30M 0.30M
Capital stock 0.32M 0.32M 0.31M 0.30M 0.30M
Retained earnings -34.22500M -216.50700M -447.57000M -559.35100M -880.36300M
Other liab 68.53M 16.76M 4.48M 8.94M 17.18M
Good will 63.68M 63.68M 63.68M 63.68M 63.68M
Other assets 286.88M 197.54M 187.11M 185.32M 247.63M
Cash 501.19M 647.17M 319.22M 266.50M 314.77M
Cash and equivalents - - - - -
Total current liabilities 324.36M 337.59M 204.66M 142.75M 105.47M
Current deferred revenue 6.58M 8.74M - 106.72M 15.90M
Net debt -311.02500M -595.89700M -270.13100M -215.76200M -302.59700M
Short term debt - -8.73900M - 2.73M 56.85M
Short long term debt - - - - 2.74M
Short long term debt total 190.17M 51.27M 49.09M 50.74M 12.18M
Other stockholder equity 2536.85M 2427.56M 2321.89M 2241.95M 2168.22M
Property plant equipment 110.62M 149.15M 67.38M 48.89M 56.76M
Total current assets 1618.76M 1834.75M 1445.39M 1011.19M 897.02M
Long term investments 756.73M 371.11M 332.31M 536.38M 157.19M
Net tangible assets 2424.74M 2048.76M 1815.43M 1622.29M 1223.77M
Short term investments 807.27M 819.90M 887.32M 585.74M 378.56M
Net receivables 214.78M 282.65M 160.88M 119.07M 178.83M
Long term debt - - - - 12.10M
Inventory 33.30M 27.49M 20.97M 12.89M 9.84M
Accounts payable 32.67M 24.26M 23.63M 11.58M 10.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -14.52100M -0.75800M 4.48M 3.07M -0.70100M
Additional paid in capital - - - - -
Common stock total equity 0.32M - 0.31M 0.30M 0.30M
Preferred stock total equity - - - - -
Retained earnings total equity -34.22500M - -447.57000M -559.35100M -880.36300M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 290.58M 131.00M 71.85M 11.31M 3.52M
Deferred long term asset charges - - - - -
Non current assets total 1452.73M 781.49M 691.94M 874.48M 525.27M
Capital lease obligations 190.17M 51.27M 49.09M 50.74M 12.18M
Long term debt total - - - - 0.08M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -385.95800M 21.34M -100.87000M -574.41300M -264.86100M
Change to liabilities -37.22300M 66.10M 51.11M 44.12M 14.15M
Total cashflows from investing activities -524.41400M -42.88400M -131.21500M -587.24700M -297.85000M
Net borrowings - - - - -0.01300M
Total cash from financing activities 0.59M -14.80100M -25.13200M 12.55M 9.69M
Change to operating activities -91.32400M 30.42M -25.83100M -5.72300M -8.52500M
Net income 182.28M 231.06M 111.78M 321.01M 690.07M
Change in cash -161.21400M 343.12M 52.63M -47.73800M 127.56M
Begin period cash flow 663.89M 320.77M 268.14M 315.88M 188.31M
End period cash flow 502.68M 663.89M 320.77M 268.14M 315.88M
Total cash from operating activities 362.61M 400.80M 208.98M 526.96M 415.72M
Issuance of capital stock - - - - -
Depreciation 20.88M 13.63M 9.14M 8.35M 7.77M
Other cashflows from investing activities -110.75000M -10.00000M -10.00000M -574.41300M 0.31M
Dividends paid - - - - -
Change to inventory -11.68300M -13.20900M -21.89700M -5.73100M -3.18100M
Change to account receivables 66.85M -122.32400M -42.47000M 43.72M -85.47100M
Sale purchase of stock 23.89M 24.31M 24.89M 22.50M -314.77500M
Other cashflows from financing activities -47.18600M -39.10800M -25.13200M -9.94600M 9.70M
Change to netincome 153.94M 195.12M 123.37M 127.69M -206.05200M
Capital expenditures 138.46M 64.22M 30.34M 12.83M 33.30M
Change receivables 66.85M - -42.47000M 43.72M -89.88100M
Cash flows other operating -12.42700M - -22.05200M -12.20500M 5.70M
Exchange rate changes - - - - -
Cash and cash equivalents changes -161.21400M - 52.63M -47.73800M 127.56M
Change in working capital -12.79900M -39.01300M -40.14000M 67.08M -79.76300M
Stock based compensation 107.57M 119.82M 105.07M 56.60M 44.32M
Other non cash items 125.04M 28.77M 7.87M 2.91M -2.56700M
Free cash flow 224.16M 336.58M 178.64M 514.12M 382.42M


  • Previous Close 20.72
  • Market Cap7413.62M
  • Volume1161385
  • P/E Ratio82.21
  • Dividend Yield2.47%
  • EBITDA66.16M
  • Revenue TTM1774.47M
  • Revenue Per Share TTM5.51
  • Gross Profit TTM 1553.15M
  • Diluted EPS TTM0.29

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Exelixis Inc
0.04 0.22% 20.77 82.21 22.73 4.09 3.10 3.58 95.92
Novo Nordisk A/S
3.64 3.01% 124.57 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
5.12 4.29% 124.40 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
7.83 1.87% 427.46 30.40 24.75 10.68 6.25 9.52 20.36
1.03 1.11% 93.74 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News


Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis Inc

1851 Harbor Bay Parkway, Alameda, CA, United States, 94502

Key Executives

Name Title Year Born
Dr. Stelios Papadopoulos Ph.D. Co-Founder & Independent Chair of the Board 1948
Dr. Michael M. Morrissey Ph.D. CEO, Pres & Director 1961
Mr. Christopher J. Senner Exec. VP & CFO 1968
Dr. Peter Lamb Ph.D. Exec. VP of Scientific Strategy & Chief Scientific Officer 1961
Mr. Jeffrey J. Hessekiel J.D. Exec. VP, Gen. Counsel & Sec. 1969
Mr. Patrick J. Haley M.B.A., MBA Exec. VP of Commercial 1976
Dr. Dana T. Aftab Ph.D. Exec. VP of Bus. Operations NA
Ms. Susan T. Hubbard Exec. VP of Public Affairs & Investor Relations NA
Mr. Gregg Bernier VP of Marketing NA
Ms. Laura Dillard Exec. VP of HR NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).